ArticleOncology letters2016

Concomitant essential thrombocythemia with JAK2 V617F mutation in a patient with chronic myeloid leukemia with major molecular response with imatinib and long-term follow-up.

Katia Borgia Barbosa Pagnano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.